Protagonist Therapeutics (PTGX) has grabbed investor attention after swinging to profitability in its latest results, reporting third quarter net income of US$220.02 million and positive earnings per share from continuing operations.
Despite the strong third quarter headline, Protagonist Therapeutics shares have eased in the short term. The 7 day share price return is down 5.94% and the 90 day share price return is down 10.94%, even as the year to date share price return is 54.69% and the 3 year total shareholder return is around 7x. This points to long term momentum that remains intact while near term expectations and risk perceptions reset after a sharp multi year run.
Compare this sharp swing to profit at Protagonist Therapeutics with other potential turnaround stories by scanning our curated list of 20 high quality undiscovered gems that are still off most investors' radar.
The recent pullback comes right after Protagonist Therapeutics shifted from losses to sizeable profits, which puts a spotlight on a simple tension: Are you seeing a cooler mood around the stock, or a cooler view on the business?
Most Popular Narrative: 26% Undervalued
At a last close of $134.86 against a narrative fair value of $182.21, the analyst consensus Narrative on Simply Wall St frames Protagonist Therapeutics as materially undervalued and links that gap directly to long term royalty and pipeline expectations.
The transition to a royalty and milestone funded model, with around US$850 million in cash and no anticipated equity based financings in the foreseeable future, gives Protagonist Therapeutics room to advance its pipeline and run a US$300 million share repurchase program. This can influence per share earnings metrics even if total profit is unchanged.
See why 3 investors see Protagonist Therapeutics as 26% undervalued.
Result: Fair Value of $182.21 (UNDERVALUED)
Still, the narrative around Protagonist Therapeutics depends heavily on partner driven royalties from ICOTYDE and MIMRYLO, as well as on early stage assets like PN-881 delivering clean clinical data.
Find out about the key risks to this Protagonist Therapeutics narrative.
Another View: What Protagonist Therapeutics’ P/E Is Telling You
The first story paints Protagonist Therapeutics as undervalued against a narrative fair value of $182.21. A simple P/E check tells a stricter story. The stock trades at 25.7x earnings versus a fair ratio of 23.9x and 15.4x for the wider US Biotechs group, which points to a rich valuation that leaves less room for disappointment if royalty or pipeline milestones slip.
If you want to see what the numbers imply for this price gap in more detail, it is worth looking at our valuation breakdown, starting with See what the numbers say about this price — find out in our valuation breakdown..
You can then put those comparisons in context with how NasdaqGM:PTGX trades against the broader sector using
Next Steps
Reading through the mixed signals on Protagonist Therapeutics and wondering what really matters most for you? The fastest way to cut through the noise is to check the full balance of risks and upsides for yourself with 4 key rewards and 1 important warning sign.
Looking for more Protagonist Therapeutics sized ideas?
If Protagonist Therapeutics has sharpened your appetite for opportunity, do not stop here. Fresh ideas often come from widening the search beyond familiar tickers.
- Target sturdier portfolios by filtering for companies with resilient finances using the 30 resilient stocks with low risk scores.
- Zero in on potential mispricings by checking a curated set of quality businesses trading below fair value through the 32 high quality undervalued stocks.
- Strengthen your income stream by scanning reliable payers with attractive yields using the 6 dividend fortresses.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com